Copertina

Real‐World Data Analysis on Early Mortality in Chinese Multiple Myeloma Patients: Analysis of 1093 Patients During a 15‐Year Period

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Xue Yang, Pu Wang, Tianhong Xu, Chenqi Yu, Yang Yang, Peng Liu
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Hematological Oncology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study
di: Enrica Antonia Martino, et al.
Pubblicazione: (2025)

Multiple Myeloma Unpacked
di: Francesca Gay, et al.
Pubblicazione: (2025)

The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non–Secretory Relapse—A Retrospective Cohort Study
di: Iuliana Vaxman, et al.
Pubblicazione: (2026)

Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data
di: Minna Harmanen, et al.
Pubblicazione: (2025)

Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study
di: Dong Liang, et al.
Pubblicazione: (2025)

Cutting‐Edge Technologies to Decode Tumor Microenvironment in Multiple Myeloma
di: Doriana Gramegna, et al.
Pubblicazione: (2026)

Correction to Elotuzumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended Follow‐Up of a Multicenter, Retrospective Real‐World Experience With 321 Cases Outside of Controlled Clinical Trials
Pubblicazione: (2025)

Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis
di: Lucio N. Gordan, et al.
Pubblicazione: (2025)

Role of Radiotherapy in the Era of Novel Immune‐Based Treatment Strategies for Multiple Myeloma
di: Tom Schlusemann, et al.
Pubblicazione: (2026)

Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis
di: Michèle Hoffmann, et al.
Pubblicazione: (2025)

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study
di: Ernesto Vigna, et al.
Pubblicazione: (2025)

Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T‐Cell Therapies in Multiple Myeloma
di: Zhiqiang Song, et al.
Pubblicazione: (2026)

A Novel Prognostic Score for Disease Progression and Mortality in Patients With Newly Diagnosed Primary Large B‐Cell Lymphoma of Immune‐Privileged Sites
di: Ganggang Wang, et al.
Pubblicazione: (2025)

Evaluation of Delayed Initiation of Lenalidomide Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
di: Koji Kawamura, et al.
Pubblicazione: (2025)

MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia
di: Jana Gregorova, et al.
Pubblicazione: (2025)

Long‐Term Real‐World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results
di: Prokop Vodicka, et al.
Pubblicazione: (2025)

CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy
di: J.T. Jutzi, et al.
Pubblicazione: (2025)

Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients
di: Jinyan Xiao, et al.
Pubblicazione: (2025)

Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma
di: Yutaka Shimazu, et al.
Pubblicazione: (2025)

A Multicenter Real‐World Retrospective Study for Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, and Prednisolone for Previously Untreated Patients With CD30‐Positive Adult T‐Cell Leukemia‐Lymphoma
di: Masahito Tokunaga, et al.
Pubblicazione: (2025)

International Cost‐Effectiveness Analysis of Nivolumab Versus Brentuximab Vedotin for Patients With Advanced‐Stage Classic Hodgkin's Lymphoma
di: Youwen Zhu, et al.
Pubblicazione: (2026)

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate‐1‐Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)
di: Paola Guglielmelli, et al.
Pubblicazione: (2026)

Efferocytosis and M2 Macrophage Polarization Gene Expression Correlates With Relapsed and Refractory Classical Hodgkin Lymphoma Patients: A Multi‐Omic Analysis
di: Juan Quarroz Braghini, et al.
Pubblicazione: (2025)

Acalabrutinib in High‐Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real‐Life Experience
di: Idanna Innocenti, et al.
Pubblicazione: (2025)

Early Detection and Central Nervous System Prophylaxis in Patients With High‐Risk Features of Primary Lymphoma of the Female Genital Tract: The Key to Improved Prognosis
di: Bingyi Wang, et al.
Pubblicazione: (2025)

Outcome of Adult Lymphoblastic Lymphoma Patients Treated in the Real Life According to the Gimema LAL1913 Protocol: A Campus ALL Multicenter Study
di: M. Delia, et al.
Pubblicazione: (2025)

Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching‐Adjusted Indirect Analysis
di: Fenghua Gao, et al.
Pubblicazione: (2025)

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T
di: Inna Y. Gong, et al.
Pubblicazione: (2026)

616 | REAL‐WORLD BURDEN OF DISEASE, TREATMENT (tx) PATTERNS, AND OUTCOMES IN PATIENTS WITH MANTLE CELL LYMPHOMA
di: A. Alencar, et al.
Pubblicazione: (2025)

Clinical Outcomes in Double‐Exposed Chronic Lymphocytic Leukemia Patients in Italy
di: Francesco Autore, et al.
Pubblicazione: (2026)

811 | RAPID STEP‐UP DOSING SCHEDULE OF GLOFITAMAB IS SAFE AND EFFICACIOUS IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
di: J. Yang, et al.
Pubblicazione: (2025)

Long‐Term Follow‐Up of Chidamide With Chemotherapy in Untreated Peripheral T‐Cell Lymphoma: One Single Center Real‐World Study in China
di: Jiajie He, et al.
Pubblicazione: (2026)

Toxicity and Tolerability of the OEPA/COPDAC Regimen in Children and Adolescents With Hodgkin Lymphoma: A Real‐World Experience
di: Hala Bekhit, et al.
Pubblicazione: (2025)

Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real‐World Study
di: Ben Varon, et al.
Pubblicazione: (2026)

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma
di: Meirav Kedmi, et al.
Pubblicazione: (2024)

Implications of Genetic, Biological and Clinical Parameters in Patients With Richter Syndrome: A Monocentric Experience
di: Idanna Innocenti, et al.
Pubblicazione: (2024)

A SWOT‐Consensus for CAR‐T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection
di: Monia Marchetti, et al.
Pubblicazione: (2025)

544 | COMPARATIVE EFFICACY OF ZANUBRUTINIB VERSUS FIXED‐DURATION ACALABRUTINIB PLUS VENETOCLAX FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
di: T. Munir, et al.
Pubblicazione: (2025)

551 | A NETWORK META‐ANALYSIS OF EFFICACY OF ZANUBRUTINIB VERSUS FIXED‐DURATION ACALABRUTINIB PLUS VENETOCLAX IN TREATMENT‐NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA
di: M. Shadman, et al.
Pubblicazione: (2025)

Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital
di: Caroline Le Lan, et al.
Pubblicazione: (2024)